Lineage Cell Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.31
- Today's High:
- $1.35
- Open Price:
- $1.33
- 52W Low:
- $1.02
- 52W High:
- $1.58
- Prev. Close:
- $1.33
- Volume:
- 281636
Company Statistics
- Market Cap.:
- $234.48 million
- Book Value:
- 0.417
- Revenue TTM:
- $10.52 million
- Operating Margin TTM:
- -157.03%
- Gross Profit TTM:
- $13.98 million
- Profit Margin:
- -209.27%
- Return on Assets TTM:
- -8.34%
- Return on Equity TTM:
- -28.92%
Company Profile
Lineage Cell Therapeutics Inc had its IPO on 1992-03-06 under the ticker symbol LCTX.
The company operates in the Healthcare sector and Biotechnology industry. Lineage Cell Therapeutics Inc has a staff strength of 70 employees.
Stock update
Shares of Lineage Cell Therapeutics Inc opened at $1.33 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.31 - $1.35, and closed at $1.32.
This is a -0.75% slip from the previous day's closing price.
A total volume of 281,636 shares were traded at the close of the day’s session.
In the last one week, shares of Lineage Cell Therapeutics Inc have slipped by -1.49%.
Lineage Cell Therapeutics Inc's Key Ratios
Lineage Cell Therapeutics Inc has a market cap of $234.48 million, indicating a price to book ratio of 2.7774 and a price to sales ratio of 16.0768.
In the last 12-months Lineage Cell Therapeutics Inc’s revenue was $10.52 million with a gross profit of $13.98 million and an EBITDA of $-15819000. The EBITDA ratio measures Lineage Cell Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Lineage Cell Therapeutics Inc’s operating margin was -157.03% while its return on assets stood at -8.34% with a return of equity of -28.92%.
In Q2, Lineage Cell Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 29.2%.
Lineage Cell Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.13 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Lineage Cell Therapeutics Inc’s profitability.
Lineage Cell Therapeutics Inc stock is trading at a EV to sales ratio of 11.3263 and a EV to EBITDA ratio of -3.59. Its price to sales ratio in the trailing 12-months stood at 16.0768.
Lineage Cell Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $111.69 million
- Total Liabilities
- $16.05 million
- Operating Cash Flow
- $19.16 million
- Capital Expenditure
- $256000
- Dividend Payout Ratio
- 0%
Lineage Cell Therapeutics Inc ended 2024 with $111.69 million in total assets and $0 in total liabilities. Its intangible assets were valued at $111.69 million while shareholder equity stood at $72.67 million.
Lineage Cell Therapeutics Inc ended 2024 with $21.96 million in deferred long-term liabilities, $16.05 million in other current liabilities, 448249000.00 in common stock, $-372971000.00 in retained earnings and $10.67 million in goodwill. Its cash balance stood at $33.89 million and cash and short-term investments were $45.93 million. The company’s total short-term debt was $987,000 while long-term debt stood at $0.
Lineage Cell Therapeutics Inc’s total current assets stands at $48.49 million while long-term investments were $0 and short-term investments were $12.04 million. Its net receivables were $443000.00 compared to accounts payable of $2.19 million and inventory worth $0.
In 2024, Lineage Cell Therapeutics Inc's operating cash flow was $19.16 million while its capital expenditure stood at $256000.
Comparatively, Lineage Cell Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.32
- 52-Week High
- $1.58
- 52-Week Low
- $1.02
- Analyst Target Price
- $5.5
Lineage Cell Therapeutics Inc stock is currently trading at $1.32 per share. It touched a 52-week high of $1.58 and a 52-week low of $1.58. Analysts tracking the stock have a 12-month average target price of $5.5.
Its 50-day moving average was $1.39 and 200-day moving average was $1.38 The short ratio stood at 12.99 indicating a short percent outstanding of 0%.
Around 442.1% of the company’s stock are held by insiders while 4106.2% are held by institutions.
Frequently Asked Questions About Lineage Cell Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.